IDEXX CEO Calls $15 Cancer Screen 'One Of The Most Consequential Innovations' In Company History
Mike Erickson says CancerDx is becoming a multi-cancer panel, and IDEXX raised its 2026 revenue range to $4,741,000,000 to $4,767,000,000.
IDEXX Laboratories, which makes diagnostic products and services mainly for veterinary clinics, is betting its CancerDx blood test can drive routine testing volume, CEO Mike Erickson said on the company's earnings call Monday. The company raised its full-year EPS outlook to $14.96 to $15.16, and shares were up about 19% to $655.05 in Monday trading.
A cancer screen priced at $15
Erickson told analysts that CancerDx is "one of the most consequential innovations in the history of the company," with more than 14,000 customers having ordered and run it. The company does not split that figure further, he said.
The expanded panel is priced "as low as $15" in the U.S. when run with most blood work panels in IDEXX reference labs. Erickson said doctors and pet parents "should never have to choose between early cancer screening and wellness blood work."
Of CancerDx runs, 70% are part of a broader blood work panel, he said, and customers who adopt it see higher routine testing volumes. He added that more than 20% of runs come from customers who do not primarily use IDEXX reference labs, which he called an opening to a conversation about the lab.
Hemangiosarcoma is next
Canine mast cell tumor detection joined canine lymphoma on the panel in late September, which Erickson said took CancerDx from a test to a multi-cancer panel. Hemangiosarcoma detection is due by the end of the year, with broad North American availability planned beginning in the first quarter.
With it, CancerDx would address approximately 40% of all canine cancers, Erickson said, calling it "a tipping point for affordable cancer screening."
Raised outlook and a pricing question
CFO Andrew Emerson said IDEXX raised its full-year revenue range to $4,741,000,000 to $4,767,000,000, up $32 million at the midpoint, including about $5 million from the Covet acquisition. Third-quarter organic revenue rose 10%, and EPS was $4.01, up 18% as reported.
Asked by a BNP Paribas analyst whether diagnostics pricing would hold as the animal-pharma leader acts on prices, Erickson declined to comment on pharmaceuticals and said IDEXX treats price as a measure of value. Emerson said pricing expectations are unchanged from early in the year.
Erickson said growth "doesn't rely on seeing positive visits." Emerson cited muted puppy and kitten adoption, offset by aging pets.
IDEXX will detail its next point-of-care platform, Multi-Q Dx, at an investor event at VMX in Orlando on Monday, January 18, at 1 p.m. Eastern.
Sources
- Idexx Labs Barks Up A Third-Quarter Beat; Can It Fetch This Next Bullish Move? | Investor's Business Daily — investors.com
- Idexx: Q3 Earnings Snapshot — Associated Press
- IDEXX Labs beats estimates, raises guidance as stock gains — Yahoo Finance
- IDEXX Laboratories Shares Rise 2.57% as Q3 Earnings Beat Forecasts and FY2026 Guidance Increases — Yahoo Finance
- IDEXX Laboratories Announces Third Quarter Results – Company Announcement - FT.com — Financial Times